期刊
CNS NEUROSCIENCE & THERAPEUTICS
卷 18, 期 3, 页码 227-237出版社
WILEY
DOI: 10.1111/j.1755-5949.2011.00259.x
关键词
Aniconvulsants; Antidepressants; Antipsychotics; Bipolar disorder; Evidence-based guidelines; Lithium; Mania; Mood stabilizers; Treatment
资金
- AstraZeneca
- Pfizer Foundation
Defining refractoriness in bipolar disorder is complex and should concern and include either every phase and pole or the disorder as a whole. The data on the treatment of refractory bipolar patients are sparse. Combination and add-on studies suggest that in acutely manic patients partial responders to lithium, valproate, or carbamazepine, a good strategy would be to add haloperidol, risperidone, olanzapine, quetiapine, or aripiprazole. Adding oxcarbazepine to lithium is also a choice. There are no reliable data concerning the treatment of refractory bipolar depressives and also there is no compelling data for the maintenance treatment of refractory patients. It seems that patients stabilized on combination treatment might do worse if shifted from combination. Conclusively there are only limited and sometimes confusing data on the treatment of refractory bipolar patients. Further focused research is necessary on this group of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据